(NASDAQ:CELC), Presented detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Medical Oncology (“ESMO”) Congress Presented updated clinical results from the Phase 1b portion of a clinical trial evaluating gedatolisib in combination with Nubeqa(R) […]
(NASDAQ:AENT), Revenue up 11% to $254M, driven by strength in physical media and collectibles Adjusted EBITDA up 259% to $12.2M; Gross Margin expands 340 basis points to 14.6% Net Income increased to $4.9M, or $0.10 per share, compared to $0.4M in Q1 FY25 AI Implementation delivering early productivity gains across sales and operations Strengthened balance
(NASDAQ:IBIO), Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human primate data for our potentially first-in-class Activin E antibody, IBIO-610, which may enable only twice-yearly dosing for the treatment of obesity SAN DIEGO,
(NASDAQ:CLBT),(NASDAQ:CLBTW), ARR grew 19% to $439.8 million; Revenue grew 18% to $126.0 million Net income of $20.2 million supports non-GAAP net income of $36.9 million and adjusted EBITDA of $37.7 million, 29.9% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress GlobeNewswire November 12, 2025 Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platform Realigned pipeline priorities by ending development of lorigerlimab in prostate cancer while
374Water Reports Third Quarter 2025 Financial Results GlobeNewswire November 12, 2025 Third Quarter Revenues Increased to $0.8 Million Due to Higher Service Revenues and Expects 2025 Full Year Revenues of Approximately $4 Million Fortified Balance Sheet Including $7.0 Million ATM Facility Extends Cash Runway into Q2 2026 Management to Host Webcast and Conference Call Today
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results GlobeNewswire November 12, 2025 â— Q3 Revenue of $8.8 million â— Q3 Cash Collections of $10.0 million â— Q3 Thyroid test volume up 12% year-over-year to record levels â— Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels PARSIPPANY, NJ, Nov. 12, 2025
Ascendis Pharma Reports Third Quarter 2025 Financial Results GlobeNewswire November 12, 2025 – Q3 2025 revenue of EUR143.1 million for YORVIPATH(R) and EUR50.7 million for SKYTROFA(R) – Q3 2025 operating profit of EUR11.0 million – TransCon(R) CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30,
Bitdeer Announces Proposed Registered Direct Offering of Class A Ordinary Shares GlobeNewswire November 12, 2025 SINGAPORE, Nov. 12, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (Nasdaq: BTDR) (“Bitdeer“), a world-leading technology company for Bitcoin mining and AI cloud, today announced that it intends to offer, subject to market and other conditions, shares of its Class
(NASDAQ:ERAS), U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D., to chief scientific officer Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $362